{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T21:47:17Z","timestamp":1773784037270,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40744-025-00824-z","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:29:27Z","timestamp":1768919367000},"page":"329-346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patients\u2019 Perspectives Regarding Ankylosing Spondylitis Treatment Administration Features: Evidence from Qualitative Interviews and a Multinational Quantitative Preference Survey"],"prefix":"10.1007","volume":"13","author":[{"given":"Atul","family":"Deodhar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine C.","family":"Maculaitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis","family":"Kopenhafer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Beusterien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You-Li","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett","family":"Hauber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph C.","family":"Cappelleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Yndestad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence rick","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa","family":"Zayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"1","key":"824_CR1","first-page":"78","volume":"7","author":"C Popescu","year":"2014","unstructured":"Popescu C, Trandafir M, B\u0103dic\u0103 A, Morar F, Prede\u0163eanu D. Ankylosing spondylitis functional and activity indices in clinical practice. J Med Life. 2014;7(1):78\u201383.","journal-title":"J Med Life"},{"key":"824_CR2","unstructured":"Cleveland Clinic. Ankylosing spondylitis (AS) (2023). Retrieved from: https:\/\/my.clevelandclinic.org\/health\/diseases\/16595-ankylosing-spondylitis-as [last accessed: March 14, 2025]."},{"issue":"3","key":"824_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/acr.25267","volume":"76","author":"M Magrey","year":"2024","unstructured":"Magrey M, Wei JC, Yndestad A, et al. Relationships of work productivity and activity impairment with patient-reported outcomes in ankylosing spondylitis: results from two trials. Arthritis Care Res (Hoboken). 2024;76(3):359\u201365.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"824_CR4","first-page":"1008","volume":"28","author":"A Ogdie","year":"2022","unstructured":"Ogdie A, Hwang M, Veeranki P, et al. Association of health care utilization and costs with patient-reported outcomes in patients with ankylosing spondylitis. J Manag Care Spec Pharm. 2022;28(9):1008\u201320.","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"824_CR5","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599\u2013613.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"824_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19\u201334.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"824_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/rheumatology\/kead634","volume":"64","author":"C Webers","year":"2025","unstructured":"Webers C, Nezam El-Din R, Beckers E, Been M, Vonkeman HE, van Tubergen A. Factors associated with treatment intensification in patients with axial spondyloarthritis and high disease activity in clinical practice. Rheumatology (Oxford). 2025;64(1):91\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"824_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.reuma.2022.01.004","volume":"19","author":"E de Miguel","year":"2023","unstructured":"de Miguel E, Fern\u00e1ndez-Carballido C, Gratac\u00f3s J, et al. Disease control in patients with ankylosing spondylitis in real clinical practice in Spain: results of the MIDAS study. Reumatol Clin (Engl Ed). 2023;19(2):99\u2013105.","journal-title":"Reumatol Clin (Engl Ed)"},{"issue":"3","key":"824_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.47196\/rar.v31i3.392","volume":"31","author":"D Capelusnik","year":"2020","unstructured":"Capelusnik D, Schneeberger EE, Mac\u00edas Oviedo LL, Sevillano Guti\u00e9rrez JM, Citera G. Preferencias del tratamiento en pacientes con espondiloartritis axial. Rev Argent Reumatol. 2020;31(3):24\u201330.","journal-title":"Rev Argent Reumatol"},{"issue":"4","key":"824_CR10","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s10067-019-04843-4","volume":"39","author":"KA Ho","year":"2020","unstructured":"Ho KA, Acar M, Puig A, Hutas G, Fifer S. What do Australian patients with inflammatory arthritis value in treatment? A discrete choice experiment. Clin Rheumatol. 2020;39(4):1077\u201389.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"824_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/acr2.11151","volume":"2","author":"W Joo","year":"2020","unstructured":"Joo W, Almario CV, Ishimori M, et al. Examining treatment decision-making among patients with axial spondyloarthritis: insights from a conjoint analysis survey. ACR Open Rheumatol. 2020;2(7):391\u2013400.","journal-title":"ACR Open Rheumatol"},{"key":"824_CR12","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.2147\/PPA.S168458","volume":"12","author":"L Scalone","year":"2018","unstructured":"Scalone L, Sarzi-Puttini P, Sinigaglia L, et al. Patients\u2019, physicians\u2019, nurses\u2019, and pharmacists\u2019 preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases. Patient Prefer Adherence. 2018;12:2153\u201368.","journal-title":"Patient Prefer Adherence"},{"key":"824_CR13","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286\u201391.","journal-title":"J Rheumatol"},{"key":"824_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114523","volume":"292","author":"MM Hennink","year":"2022","unstructured":"Hennink MM, Kaiser BN. Sample sizes for saturation in qualitative research: a systematic review of empirical tests. Soc Sci Med. 2022;292:114523.","journal-title":"Soc Sci Med"},{"key":"824_CR15","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9781107337855","volume-title":"Best\u2013worst scaling: theory, methods and applications","author":"JJ Louviere","year":"2015","unstructured":"Louviere JJ, Flynn TN, Marley AA. Best\u2013worst scaling: theory, methods and applications. Cambridge, UK: Cambridge University Press; 2015."},{"key":"824_CR16","volume-title":"Applied MaxDiff: a practitioner's guide to best\u2013worst scaling","author":"K Chrzan","year":"2019","unstructured":"Chrzan K, Orme BK. Applied MaxDiff: a practitioner\u2019s guide to best\u2013worst scaling. Provo, UT: Sawtooth Software, Inc.; 2019."},{"issue":"1","key":"824_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jhealeco.2006.04.002","volume":"26","author":"TN Flynn","year":"2007","unstructured":"Flynn TN, Louviere JJ, Peters TJ, Coast J. Best\u2013worst scaling: what it can do for health care research and how to do it. J Health Econ. 2007;26(1):171\u201389.","journal-title":"J Health Econ"},{"issue":"4","key":"824_CR18","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JF Bridges","year":"2011","unstructured":"Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403\u201313.","journal-title":"Value Health"},{"issue":"1","key":"824_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"FR Johnson","year":"2013","unstructured":"Johnson FR, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16(1):3\u201313.","journal-title":"Value Health"},{"issue":"4","key":"824_CR20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber AB, Gonz\u00e1lez JM, Groothuis-Oudshoorn CG, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health. 2016;19(4):300\u201315.","journal-title":"Value Health"},{"issue":"2","key":"824_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u201381.","journal-title":"Qual Res Psychol"},{"issue":"2","key":"824_CR22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/002224379503200203","volume":"32","author":"GM Allenby","year":"1995","unstructured":"Allenby GM, Arora N, Ginter JL. Incorporating prior knowledge into the analysis of conjoint studies. J Mark Res. 1995;32(2):152\u201362.","journal-title":"J Mark Res"},{"issue":"1","key":"824_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13561-015-0079-x","volume":"6","author":"AC M\u00fchlbacher","year":"2016","unstructured":"M\u00fchlbacher AC, Kaczynski A, Zweifel P, Johnson FR. Experimental measurement of preferences in health and healthcare using best\u2013worst scaling: an overview. Health Econ Rev. 2016;6(1):2.","journal-title":"Health Econ Rev"},{"issue":"8","key":"824_CR24","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","volume":"80","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021;80(8):1004\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"824_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0311798","volume":"19","author":"Y Li","year":"2024","unstructured":"Li Y, Ma D, Yang L. Experiences and perceptions of patients with ankylosing spondylitis: a systematic review and meta-synthesis of qualitative studies. PLoS ONE. 2024;19(10):e0311798.","journal-title":"PLoS ONE"},{"key":"824_CR26","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.2147\/PPA.S463354","volume":"18","author":"JT Myers","year":"2024","unstructured":"Myers JT, Dam JV, Imran M, Hashim M, Dhalla AK. Preference for a novel oral alternative to parenterally administered medications. Patient Prefer Adherence. 2024;18:1547\u201362.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"824_CR27","first-page":"42","volume":"1","author":"RN Cunha","year":"2022","unstructured":"Cunha RN, Vieira-Sousa E, Khmelinskii N, et al. Sex differences in axial spondyloarthritis: data from a Portuguese spondyloarthritis cohort. ARP Rheumatol. 2022;1(1):42\u20138.","journal-title":"ARP Rheumatol"},{"issue":"1","key":"824_CR28","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13075-023-03173-w","volume":"25","author":"M Hallstr\u00f6m","year":"2023","unstructured":"Hallstr\u00f6m M, Klingberg E, Deminger A, Rehnman JB, Geijer M, Forsblad-d\u2019Elia H. Physical function and sex differences in radiographic axial spondyloarthritis: a cross-sectional analysis on Bath Ankylosing Spondylitis Functional Index. Arthritis Res Ther. 2023;25(1):182.","journal-title":"Arthritis Res Ther"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00824-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00824-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00824-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:05:55Z","timestamp":1773770755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00824-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["824"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00824-z","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Atul Deodhar: Consulting and Advisory Boards for Bristol Myers Squibb, Eli Lilly, J&J, Novartis, Pfizer, and UCB; Research Grants: Bristol Myers Squibb, Eli Lilly, J&J, MoonLake, Novartis, Pfizer, and UCB. You-Li Ling, Brett Hauber, Joseph C. Cappelleri, Arne Yndestad, and Mostafa Zayed: Employed by and owns stock\/stock options in Pfizer. Lawrence Rick Phillips: No conflicts of interest to disclose. Martine C. Maculaitis, Lewis Kopenhafer, and Kathleen Beusterien: Employed by Oracle Life Sciences, which provides consulting services to Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol, qualitative interview discussion guide, informed consent statement, and quantitative survey were reviewed by Sterling IRB (Atlanta, Georgia, US), and an exemption determination was granted on July 26, 2022 (IRB ID #: 10267-MMaculaitis). To participate in either the qualitative interviews or the quantitative survey, patients provided their informed consent verbally or electronically, respectively. The study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}